Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MEK Mutation”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Not applicableStudy completedNCT04039672
What this trial is testing

Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma

Who this might be right for
Melanoma
Hospices Civils de Lyon 10
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Testing effectiveness (Phase 2)Ended earlyNCT04198818
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Who this might be right for
Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more
Haihe Biopharma Co., Ltd. 37
Testing effectiveness (Phase 2)Study completedNCT01336634
What this trial is testing

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Who this might be right for
Cancer
Novartis Pharmaceuticals 177
Early research (Phase 1)Ended earlyNCT02049801
What this trial is testing

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)+12 more
Bruno C. Medeiros 1
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557956
What this trial is testing

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma
National Cancer Institute (NCI) 16
Early research (Phase 1)Study completedNCT03434262
What this trial is testing

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic Ganglioglioma+53 more
St. Jude Children's Research Hospital 68
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Testing effectiveness (Phase 2)Ended earlyNCT01085331
What this trial is testing

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Metastatic Colorectal Cancer
EMD Serono 16
Testing effectiveness (Phase 2)Study completedNCT02834364
What this trial is testing

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Who this might be right for
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical Center 12
Early research (Phase 1)Study completedNCT01363232
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Advanced Solid TumorsSelected Solid Tumors
Array Biopharma, now a wholly owned subsidiary of Pfizer 89
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Testing effectiveness (Phase 2)Looking for participantsNCT06229340
What this trial is testing

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Who this might be right for
RAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more
N.N. Petrov National Medical Research Center of Oncology 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05195632
What this trial is testing

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pierre Fabre Medicament 63
Testing effectiveness (Phase 2)Study completedNCT00866177
What this trial is testing

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
National Cancer Institute (NCI) 167
Testing effectiveness (Phase 2)Study completedNCT02296112
What this trial is testing

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Who this might be right for
Recurrent MelanomaStage IIIB MelanomaStage IIIC Melanoma+1 more
Vanderbilt-Ingram Cancer Center 9
Testing effectiveness (Phase 2)Study completedNCT01037127
What this trial is testing

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Who this might be right for
Cancer
GlaxoSmithKline 97
Testing effectiveness (Phase 2)Study completedNCT00888134
What this trial is testing

Selumetinib in Cancers With BRAF Mutations

Who this might be right for
Adult Solid Neoplasm
National Cancer Institute (NCI) 28
Load More Results